Adc Therapeutics SA (NYSE:ADCT)’s traded shares stood at 0.33 million during the last session, with the company’s beta value hitting 1.54. At the close of
Adc Therapeutics SA (NYSE:ADCT)’s traded shares stood at 0.31 million during the last session, with the company’s beta value hitting 1.59. At the close of
In last trading session, Adc Therapeutics SA (NYSE:ADCT) saw 0.69 million shares changing hands with its beta currently measuring 1.56. Company’s recent per share price
Adc Therapeutics SA (NYSE:ADCT)’s traded shares stood at 0.57 million during the last session, with the company’s beta value hitting 1.48. At the close of
During the last session, Adc Therapeutics SA (NYSE:ADCT)’s traded shares were 0.34 million, with the beta value of the company hitting 1.48. At the end
After receiving approval for a breakthrough medicine, ADC Therapeutics SA (NYSE: ADCT) is soaring today, up 15.70% to trade at $3.68 at the last check
Marketing Sentinel delivers exclusive content, news, articles, and comprehensive coverage of events in the USA and worldwide with a commitment to reliability, objectivity, and timeliness.
© 2024, Powered by Smart TechOne
